CAR-T clinical trials for Neuroendocrine Cancer (plus bonus section on CAR-NK)
Update 29th August 2025 Progress Seen in CDH17 CAR T Trial. Chimeric Therapeutics has reported that a neuroendocrine cancer patient in the Phase 1 clinical trial of CAR T cell therapy has experienced tumour shrinkage. In an update for investors on October 8, Chimeric reported 8 patients have been treated so far, with two more waiting for treatment. Two of the 8 have intestinal NETs. Read more here. Update 4th June 2025 CAR T-Cell Therapy for Neuroendocrine Cancer, Now in Clinical Trial, Receives FDA FAST TRACK Designation. Read more here. Update 17th October 2024 First patient dosed. Read more here.…